Table 2.
Response to PLD by baseline characteristics
| Response according RECIST after completion of PLD No. of patients (%) |
||||||||
|---|---|---|---|---|---|---|---|---|
| Characterstic | No. pts. | CR | PR | SD | PD | NE | ORR | p |
| All patients | 129 | 2 (2) | 32 (25) | 24 (19) | 62 (48) | 9 (7) | 34 (26) | |
| Age | ||||||||
| < 63 | 64 | 0 (0) | 15 (23) | 11 (17) | 36 (56) | 2 (3) | 15 (23) | NS |
| > = 63 | 64 | 2 (3) | 17 (27) | 13 (20) | 25 (39) | 7 (11) | 19 (30) | |
| Age | ||||||||
| < 50 | 17 | 0 (0) | 3 (18) | 2 (12) | 11 (65) | 1 (6) | 3 (18) | 0.382 |
| ≥50 | 112 | 2 (2) | 29 (26) | 22 (20) | 51 (46) | 8 (7) | 31 (28) | |
| No. cardiac risk factors | ||||||||
| 1 - 2 | 88 | 2 (2) | 19 (22) | 17 (19) | 43 (49) | 7 (8) | 21 (24) | 0.346 |
| ≥3 | 41 | 0 (0) | 13 (32) | 7 (17) | 19 (46) | 2 (5) | 13 (32) | |
| No. metastatic sites | ||||||||
| 1-3 | 99 | 2 (2) | 28 (28) | 21 (21) | 42 (42) | 6 (6) | 30 (30) | 0.065 |
| 4-7 | 30 | 0 (0) | 4 (13) | 3 (10) | 20 (67) | 6 (9) | 4 (13) | |
| Metastatic site | ||||||||
| Visceral | 92 | 0 (0) | 22 (24) | 15 (16) | 49 (53) | 6 (7) | 22 (24) | 0.321 |
| Nonvisceral | 37 | 2 (5) | 10 (27) | 9 (24) | 13 (35) | 3 (8) | 12 (32) | |
| Endocrine therapy | ||||||||
| No | 33 | 2 (6) | 4 (12) | 7 (21) | 6 (49) | 4 (8) | 6 (18) | 0.217 |
| Yes | 96 | 0 (0) | 28 (29) | 17 (18) | 46 (48) | 5 (5) | 28 (29) | |
| No. of prior chemos* | ||||||||
| 0 - 3 | 95 | 2 (2) | 28 (30) | 22 (23) | 38 (40) | 5 (5) | 30 (32) | 0.024 |
| ≥4 | 34 | 0 (0) | 4 (12) | 2 (6) | 24 (71) | 4 (12) | 4 (12) | |
| Prior anthracycline | ||||||||
| No | 52 | 2 (4) | 12 (23) | 14 (27) | 19 (36) | 5 (10) | 14 (27) | .904 |
| Yes | 77 | 0 (0) | 20 (26) | 10 (13) | 43 (56) | 4 (5) | 20 (26) | |
| Prior taxane | ||||||||
| No | 56 | 2 (4) | 19 (34) | 10 (18) | 21 (38) | 4 (7) | 21 (38) | 0.012 |
| Yes | 73 | 0 (0) | 13 (18) | 14 (19) | 41 (56) | 5 (7) | 13 (18) | |
*adjuvant chemotherapy was counted as prior therapy line